Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Nualtra adds experience to Ajinomoto’s medical nutrition business and is the fourth wholly owned subsidiary of Cambrooke
Ajinomoto Cambrooke has acquired Nualtra, a nutrition products company that provides oral nutritional supplements to improve life in the UK and Ireland. Cambrooke, the world leader and innovator in therapeutic nutrition for innate metabolism errors, ketogenic diet therapy, disease-related malnutrition and, more recently, severe protein allergy, continues to expand its medical nutrition portfolio with this acquisition.
“By taking advantage of Cambrooke, Ajinomoto and Nualtra’s resources, we reinforce our ability to better meet the needs of our customers and healthcare professionals. We received several interesting offers for our business, but Cambrooke was the obvious choice for everyone involved.”
Cambrooke is a wholly-owned subsidiary of Ajinomoto Health & Nutrition North America, and derives significant benefits from the Ajinomoto group’s world leader experience in amino acids, ingredient science and R&D resources for flavour enhancement. Soon, this experience will also be applied to the Nualtra portfolio.
Nualtra’s executive director (CEO) Mark Lane said of the acquisition, “By taking advantage of the resources of Cambrooke, Ajinomoto and Nualtra, we have strengthened our ability to better meet the needs of our customers and healthcare professionals. We have received several interesting offers for our business, but Cambrooke was the obvious choice for everyone involved.”
Nualtra adds experience to Ajinomoto’s medical nutrition business, led by Cambrooke, and is the fourth wholly owned subsidiary of Cambrooke, all in Europe.